Who Are We?
Wize Pharma is focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome and other inflammatory conditions.
Wize Pharma Ltd. holds rights to purchase, market, sell and distribute LO2A.
Wize Pharma Ltd. has a license to market LO2A - a drug in the field of Dry Eye, with additional indications as CCh and Sjogren Syndrom
LO2A is registered in various countries in Europe, manufactured in a certified facility and sold for more than a decade in several European countries by the inventor.
The product suggests advantage treating CCh, a disease without existing drug treatment
International market valued at billions of dollars a year
Professional, skilled and highly experienced management team
Company regularly reviews other potential projects in advanced stages of clinical proof of concept in humans
The Drug: LO2A EYE DROPS
SAFE, STERILE, EFFECTIVE
Single-dose artificial tear preparation, presented in sterile, uni-dose vials to minimize risk of infection and contamination.
Preservative-free; no material known side effects. Previous clinical studies, conducted by the inventor, has found the product to be effective in the treatment of Dry Eye Syndrome ("Dry Eye"), Conjunctivochalasis (CCh; chronic inflammation of the conjunctiva) and Sjögren’s Syndrome.